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ABSTRACT 
 
This cooperative study assessed prognostic factors for overall survival (OS) and 
risk of transformation to acute myeloid leukaemia (AML) in 541 patients with de 
novo myelodysplastic syndrome (MDS) and deletion 5q. Additional 
chromosomal abnormalities were strongly related to different patients’ 
characteristics. On multivariate analysis, the most important predictors of both 
OS and AML transformation risk were number of chromosomal abnormalities 
(P<0.001 for both outcomes), platelet count (P<0.001 and P=0.001, 
respectively), and proportion of bone marrow (BM) blasts (P<0.001 and 
P=0.016, respectively). The number of chromosomal abnormalities defined 
three risk categories for AML transformation (del(5q), del(5q)+1 and del(5q)+≥2 
abnormalities) and two for OS (one group: del(5q) & del(5q)+1; and del(5q)+≥2 
abnormalities, as the other one); with a median survival time of 58.0 and 6.8 
months; respectively. Platelet count (P=0.001) and age (P=0.034) predicted OS 
in patients with ‘5q- syndrome’. This study demonstrates the importance of 
additional chromosomal abnormalities in MDS patients with deletion 5q, 
challenges the current ‘5q- syndrome’ definition, and constitutes a useful 
reference series to properly analyze the results of clinical trials in these patients. 
 
 
Keywords: ‘5q- Syndrome’; Cytogenetics; Deletion 5q; Myelodysplastic 
syndromes 
 
 
 4
INTRODUCTION 
 
Myelodysplastic syndromes (MDS) are a group of clonal haematopoietic stem 
cell diseases characterized by dysplasia and ineffective haematopoiesis in one 
or more myeloid cell lines. MDS is associated with a variable overall survival 
(OS) and a relatively high risk of progression to acute myeloid leukaemia (AML). 
Evolution to AML and the clinical consequences of cytopenias are main causes 
of morbidity and mortality in MDS.1-3 
Although, many specific chromosomal abnormalities have been associated with 
MDS, partial or complete deletion of the long arm of chromosome 5 (deletion 
5q), with or without additional karyotypic abnormalities, is present in 10% to 
15% of patients with de novo MDS, and thus is the most frequently documented 
recurrent cytogenetic abnormality in MDS.4-8 Outcomes among MDS patients 
with deletion 5q vary greatly, both in terms of OS and risk of transformation to 
AML.5,8-11 The presence of additional chromosomal abnormalities or an excess 
of blasts shortens OS and increases the risk of AML transformation.5,8,10,11 The 
‘5q- syndrome’ is the only MDS group considered to represent a separate 
cytogenetically defined disease-category in the WHO classification. Patients 
with this syndrome, mostly females, are characterized by the presence of 
isolated deletion 5q, a blast count below 5%, favourable prognosis, and a low 
rate of AML transformation.2,3 So far, no other characteristic besides the 
proportion of bone marrow (BM) blasts and the existence of additional 
chromosomal abnormalities has been recognized and universally accepted as a 
predictor of outcome for patients with MDS and deletion 5q.10,11 Further, no 
variable has been shown to impact the clinical course of patients with WHO-
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defined ‘5q- syndrome’. Lenalidomide therapy has activity in single arm clinical 
trials in patients with International Prognostic Scoring System (IPSS) low or 
intermediate-1 risk, red blood cell transfusion dependency, and deletion 5q12-14 
leading to approval by the US Food and Drug Administration for this indication. 
In contrast, the European Medicines Agency (EMEA) refused approval of 
lenalidomide for these patients, because there was no historical data against 
which the safety of lenalidomide could be compared, especially on concerning 
the expected risk of AML transformation.15 Thus, the analysis of further 
prognostic parameters for OS and AML transformation in large series of MDS 
patients with deletion 5q is of importance. 
The major aim of this global cooperation study was to assess the characteristics 
and natural history of a large series of 541 patients with de novo MDS and 
deletion 5q in order to identify prognostic factors of outcome. 
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MATERIAL AND METHODS 
 
Patients and diagnostic criteria 
Five-hundred and forty-one patients with primary MDS and deletion 5q, included 
in the Spanish Haematological Cytogenetic Working Group/Spanish Registry of 
MDS (234 patients), German-Austrian MDS Study Group (198 patients), MD 
Anderson Cancer Center (85 patients), Tokyo Medical University (12 patients), 
and other centres participating in the International Working Group on MDS 
Cytogenetics (12 patients) databases were the subject of this analysis. Several 
patients in the present study had been included in previously published 
reports5,9,11 but without focusing on deletion 5q. Cases belonging to the Spanish 
Haematological Cytogenetic Working Group, Spanish Registry of MDS and MD 
Anderson were scrutinized and double-checked before inclusion for avoiding 
duplication.  
The cases were collected between November 1972 and September 2008. The 
diagnosis of MDS was made according to the classification proposal of the 
French-American-British (FAB) study group1. Patients with a diagnosis of 
RAEB-T or CMML by FAB criteria were excluded because they are no longer 
considered as MDS by the WHO classification system. Whenever possible, 
patients were reclassified by WHO 2001 criteria.2 Patients with an ambiguous 
diagnosis of MDS and those who had previously received chemotherapy or 
radiotherapy (therapy-related MDS) were excluded. In all patients included in 
this study, deletion 5q had been detected by conventional cytogenetics. The 
cytogenetic analysis of BM specimens was performed at the individual centres 
following standard chromosome-banding procedures, being crossed-validated 
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among centres in the previously published studies. Inclusion in the study 
required the analysis of at least 10 metaphases per case. The criteria defined 
by the International System for Human Cytogenetic Nomenclature in 2005 were 
used for identification of abnormal clones.16 For example, a karyotype was 
considered complex when more than two independent cytogenetic 
abnormalities were found. When two or more clones with two aberrations were 
noted, the patient was categorized in the complex aberration group, whereas 
patients with two karyotypically independent clones with a single change in one 
clone and two anomalies in the second one were not considered as complex 
chromosomal abnormalities. Loss of Y chromosome was considered as one 
chromosomal abnormality. In this series, an unrelated clone was defined as a 
clone with cytogenetic aberrations that did not derive from the progenitor clone 
with the deletion 5q. The unrelated clones were considered as additional 
aberrations, accompanying to the deletion 5q, for the definition of its cytogenetic 
complexity.17 All the cytogenetic information corresponding to the German-
Austrian MDS Study Group was initially reviewed by JS and DH; and the 
Spanish Haematological Cytogenetic Working Group/Spanish Registry of MDS 
cytogenetic information, by MM, BE and FS. The final revision was done by FS, 
deleting those cases with incomplete cytogenetic information. The final 
diagnosis was provided by each institution, all of them with recognized 
experience in this pathology. 
In keeping with the guidelines of the Declaration of Helsinki, this retrospective 
non-interventional study was conducted with the approval of the internal review 
board from the participating institutions belonging to each registry/cooperative 
group/centre or following individual institutional guidelines. 
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Prognostic factors 
Different patient and disease characteristics, recorded at the time of diagnosis, 
were examined in the prognostic factor analysis to establish their possible 
relationship with OS and AML transformation. Basic demographic data included 
age and sex. Haematological parameters were haemoglobin level, absolute 
neutrophil count (ANC), platelet count, number of cytopenias, and proportion of 
blast cells in BM, all of them taking cut-off points and groups defined by the 
1997 IPSS into account.10 For platelet count, an additional cut-off point of 150 x 
109/L was analyzed. Initially, we chose to test this value based on the higher 
platelet count that characterizes the ‘5q- syndrome’ and the low number of 
patients with severe thrombocytopenia in this subset. After showing its 
association with prognosis in those patients, we decided to examine its potential 
impact in the overall series as well. 
Classification systems included FAB1 and WHO 20012 classifications, and IPSS 
scoring system. The IPSS risk categories considered were those in the original 
report (low, intermediate-1, intermediate-2 and high).10 Cytogenetic findings 
recorded and analyzed were the presence of additional chromosome 
abnormalities, including the number of additional abnormalities (karyotype 
complexity) and the most prevalent specific additional abnormalities found 
(chromosome 1, chromosome 3, -7, 7q-, +8, +11, +13, 12p-, chromosome 17,   
-18/18q-, 20q-, +21, -X/-Y, and unrelated clones, taking into account if they 
were accompanying deletion 5q as a single additional chromosome abnormality 
or in the context of a complex karyotype), the proportion of metaphases carrying 
deletion 5q, and the most frequent breakpoints of the 5q deleted region 
(q13q31, q13q33, q22q33, q12q33, q14q34, and other breakpoints). Initially, the 
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number of additional chromosomal abnormalities was grouped into six 
categories: none (isolated deletion 5q), one, two, three, four, and five or more 
additional abnormalities. After showing that the clinical outcome for patients with 
two or more additional abnormalities was almost identical, only three 
cytogenetic categories were considered for all subsequent analysis: isolated 
deletion 5q, deletion 5q plus one additional abnormality, and deletion 5q plus 
two or more additional abnormalities. 
 
Statistical analysis 
Comparisons of proportions and ranks of variables between different groups 
were performed by Chi-square, Fisher’s exact, Student-t, Mann-Whitney U or 
One-Way ANOVA with post-hoc Tukey’s tests, as appropriate.  
The Kaplan-Meier product limit method was used to estimate the probability of 
OS and risk of AML transformation18-21, OS was measured from haematological 
diagnosis to death or last follow-up. All deaths, whether related or not to MDS, 
were considered as the endpoint of the follow-up interval. Patients treated with 
intensive AML-type chemotherapy (11 patients), haematopoietic stem cell 
transplantation (3 patients) or with lenalidomide (3 patients) were considered as 
censored data at the time of starting treatment, when the starting date of 
treatment was available. AML transformation was measured from diagnosis to 
AML development. Patients dying from any cause before developing AML were 
considered as censored data in the date of death for the calculation of AML 
transformation curves. To avoid any potential bias in the estimation of the risk of 
AML transformation, only patients from those registries/centres with information 
about AML evolution was available in most of instances, were included in the 
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calculation of AML transformation risk. Statistical comparisons between different 
actuarial curves were based on log-rank tests.19-21 
Multivariate analysis using the Cox proportional hazards regression method for 
temporal events was used to identify the most significant independent 
prognostic variables for OS and AML transformation.22 Characteristics selected 
for possible inclusion in the multivariate model where those for which there was 
some indication of a significant association with OS or AML transformation in 
the univariate analysis (Table 4), P<0.05. Only cases with complete data for all 
variables were included in the regression procedure. The forward stepwise 
procedure was stopped when the P value for entering an additional variable 
was above 0.05. All P values reported are two-sided. The selected P value for 
considering differences statistically significant in all analyses was <0.05. All 
analyses were performed using the statistical package SPSS version 17.0. 
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RESULTS 
 
Characteristics of the patients 
The overall series included 183 males (34%) and 358 females (66%) with a 
median age of 68 years (range, 33 – 92 years). The main characteristics of the 
patients at the time of diagnosis are summarized in Table 1. The median value 
for haemoglobin level, ANC and platelet count were 9.0 g/L (range, 2.5 – 14.0), 
1.8 x 109/L (range, 0.10 –  38.40) and 181 x 109/L (range, 4 –  1,610), 
respectively, whereas median BM blast count was 4.0%. Most of the patients 
were classified as RA (49.2%) or RAEB (42.7%) according to the FAB 
classification; and ‘5q- syndrome’ (39.7%), RAEB-2 (29.0%) or RAEB-1 (21.7%) 
by the WHO 2001 criteria.  
Two-hundred and ninety-nine patients (55.3%) had deletion 5q as the sole 
chromosomal abnormality, 93 (17.2%) had one additional abnormality, and 149 
(27.5%) had a complex karyotype with two or more associated abnormalities. 
The most frequent single additional anomalies to deletion 5q were del(12p) 
(n=11), trisomy 21 (n=10), trisomy 8 (n=9) and del(20q) (n=8). Of note, there 
were no patients with deletion 5q and loss of chromosome Y. However, as 
expected, majority of patients were females (ratio 1:2.1). In the context of 
complex karyotypes, aberrations most commonly found were those affecting 
chromosome 17 (n=40), -18/18q- (n=36), trisomy 8 (n=35), del(20q) (n=30), 
monosomy 7 (n=28), and involvement of chromosome 3 (n=25).  
Ten of the cases included in the series (2.0%) had unrelated clones (without 
deletion 5q), with trisomy 8 (4 cases) and del(12p) (2 cases), being the most 
frequent cytogenetic aberrations. 
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The most common 5q deleted regions in 383 cases, in whom this information 
was available, were q13q33 (49.4%), q13q31 (15.9%), q22q33 (7.8%) and 
20.9% other unspecific breakpoints. There was a strong correlation between the 
number of chromosomal abnormalities found in addition to deletion 5q and 
different haematological parameters, other cytogenetic findings, FAB and WHO 
subtype, and IPSS classification (Table 2). Comparing patients with ≥2 
additional abnormalities with patients belonging to a group encompassing two 
cytogenetic categories [del(5q) and del(5q)+1], we observed that there were 
differences in sex distribution (P<0.001), and haemoglobin level between both 
groups (P=0.074). Platelet count and ANC showed differences between both 
groups (P<0.001) and a higher incidence of cytopenias as well (P<0.001). The 
proportion of blasts in BM was higher (P<0.001), as well as the higher 
proportion of cases with metaphases carrying the deletion 5q (P<0.001).  
FAB and WHO diagnoses, according to the number of chromosomal 
abnormalities found in addition to deletion 5q, are shown in Figure 1. 
Apart from differences in characteristics inherent to the definition of ‘5q- 
syndrome’ (for example, absence of additional chromosomal abnormalities and 
lower proportion of blasts in BM), this subset of patients (n=148) had a higher 
median ANC (P=0.001) and median platelet count value (P<0.001) and, 
consequently, a lower number of cytopenias (P<0.001) than the remaining 
patients. Further, patients with ‘5q- syndrome’ showed a lower median 
percentage of metaphases carrying deletion 5q than the rest of the patients 
(median 70% versus 90%; P<0.001) (Table 3). No significant differences in 
breakpoints were observed between patients with ‘5q- syndrome’ and the 
remaining patients (data not shown). 
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Outcome and prognostic factors in the overall series 
Overall survival and AML transformation data were available in 512 (94.6%) and 
299 (55.3%) patients, respectively. With a median follow-up of 17.2 months 
(range, 1 – 326) for surviving patients, 258 patients remained alive and the 
median OS for the whole series was 36.8 months. Sixty-six patients evolved to 
AML during follow-up, with the actuarial risk of AML evolution at 5 years of 
38.8%. As depicted in Table 4, univariate analysis showed that both OS and 
risk of AML transformation were significantly influenced by age (P<0.001 and 
P=0.042, respectively), sex (P<0.001 and P=0.029, respectively), ANC 
(P<0.001 and P=0.004, respectively) and platelet count, number of cytopenias, 
proportion of BM blasts, FAB and WHO subtype, IPSS risk group and number 
of chromosomal abnormalities found in addition to deletion 5q (P<0.001 for all 
variables, both OS and AML evolution), as well as the percentage of 
metaphases carrying deletion 5q (P<0.001 and P=0.003, respectively). 
Additionally, OS was shorter in those with lower haemoglobin levels (P=0.030). 
Different deletion breakpoints showed an impact on outcome in terms of OS 
(P=0.008). Although, there were one breakpoint (q22q33) that showed less 
median survival time, this did not differ statistically from the rest of the 
breakpoints (P=0.228). Figure 2 shows the actuarial curves of OS (Figure 2A) 
and AML transformation (Figure 2B) in the three cytogenetic groups defined 
according to the number of chromosomal abnormalities found in addition to 
deletion 5q: isolated deletion 5q, deletion 5q plus one additional abnormality, 
and deletion 5q plus two or more additional abnormalities. As can be 
appreciated, all the three aforementioned cytogenetic groups were found to 
have a significantly different risks of AML transformation (P<0.001 for all 
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comparisons) but regarding OS only two risk groups could be clearly identified, 
patients with deletion 5q alone or with one additional chromosomal abnormality 
and patients with two or more additional abnormalities. Although patients with 
deletion 5q plus one additional abnormality had a somewhat shorter OS than 
patients with isolated deletion 5q (median OS, 63.4 and 46.0 months, 
respectively) differences in OS among these two groups were not statistically 
significant (P=0.131). We were not able to determine the potential impact in the 
outcome of any of the additional aberrations due to the low number of cases as 
a single anomaly accompanying to the deletion 5q. In contrast, patients with two 
or more additional abnormalities showed a significantly shorter OS than the 
other two groups of patients (median OS, 6.8 months; P<0.001).  
The same prognostic impact of the three cytogenetic groups, defined by the 
number of chromosomal abnormalities found in addition to deletion 5q, on OS 
and risk of AML transformation was evident when the analysis was restricted to 
patients with less than 5% and less than 10% blasts in BM (Figure 3).  
As shown in Table 5, on multivariate analysis the characteristics showing an 
independent prognostic impact concerning OS and AML transformation risk, 
were the number of chromosomal abnormalities found in addition to deletion 5q 
(P<0.001 for both outcomes); the platelet count (P<0.001 and P=0.001, 
respectively); and the proportion of blasts in BM (P<0.001 and P=0.016, 
respectively). Age and sex also added significant prognostic information for OS 
(P=0.001 and P=0.020, respectively). The independent prognostic impact of 
platelet count in multivariate analysis was observed studying this variable both 
as a dichotomous and continuous one. When this variable was introduced 
simultaneously in the regression procedure in both ways, the dichotomized 
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manner was selected for entering the model. For this reason and for practical 
purposes all results offered are those obtained with platelet count as a 
dichotomized variable. 
 
Outcome and prognostic factors in patients with ‘5q- syndrome’ 
When the analysis was restricted to 144 patients with the ‘5q- syndrome’ 
diagnosis and available follow-up data, median OS was 68.8 months and 
actuarial risk of AML transformation at 5 years was 17.1%. On univariate 
analysis, male patients (median OS, 40.9 months vs. 80.0 months for females; 
P=0.020), patients older than 60 years of age (median OS, 45.0 months vs. 
134.5 months for patients ≤ 60 years of age; P=0.005), and those with a platelet 
count lower than 150 × 109/L (median OS, 32.2 months vs. 80.0 months for 
patients with a platelet count greater than 150 × 109/L; P<0.001) had a 
significantly shorter OS.  
Multivariate analysis showed that the main factors influencing OS were platelet 
count (hazard ratio [HR], 3.2; P=0.001) and age (HR, 2.2; P=0.034). None of 
the parameters evaluated demonstrated a significant association with AML 
transformation risk neither on univariate nor multivariate analysis. 
 
Outcome and prognostic factors in patients of low and intermediate-1 risk 
Patients belonging to the low and intermediate-1 IPSS category are well-known 
considered as good prognosis, as well as those MDS with deletion 5q. 
Comparing the outcomes of both groups of patients in our series, as expected, 
low IPSS patients has a median survival time higher than the intermediate-1 
patients, though these differences were not statistically significant (58.9 months 
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vs. 45.0 months; P=0.182). The actuarial AML risk at 5 years was also similar 
(21.2% vs. 25.6%, P=0.437). Focusing on low risk patients, all presented 
isolated 5q deletion and <5% of BM blasts. The univariate analysis did not 
detect any prognostic factor regarding OS and AML, for those variables that 
there were enough patients per group. The intermediate-1 group had patients 
belonging to the three cytogenetic and BM blast count predefined categories. 
The OS univariate analysis showed the prognosis impact of cytogenetic 
categories (P=0.020), age (P=0.003) and platelet count (P=0.002). Regarding 
AML, cytogenetic categories (P=0.008) and sex (P=0.027) revealed their 
prognostic impact in the intermediate-1 subset of patients. 
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DISCUSSION 
 
In this paper we present the results of a larger multicentre cooperative study 
that recruited the largest to-date known series of de novo MDS patients with 
deletion 5q in the pre-lenalidomide era. This has allowed us to asses the clinical 
characteristics, natural history and prognostic factors, with special emphasis on 
cytogenetic findings, being the risk of transformation to AML one of the 
highlights of this study. This was one of the controversial points for the approval 
of lenalidomide by the EMEA. Although, a phase III clinical trial comparing 
lenalidomide vs. placebo has shown some preliminary data about the risk of 
AML transformation in patients treated and not treated with lenalidomide12; 
herein, we have studied extensively this parameter in non treated patients, 
taking different prognostic factors into account.  
We confirmed the strong relationship between the number of additional 
chromosomal abnormalities (apart from deletion 5q) and outcomes, and we are 
able to show that the patterns of these additional karyotype abnormalities define 
two distinct risk groups concerning the probability of OS and three concerning 
the risk of AML transformation. Platelet count and sex were the only variables 
independently associated with OS in a specific sub-analysis of patients with 
WHO-defined ‘5q- syndrome’.  
With regard to cytogenetic abnormalities, we found that the most frequent single 
additional abnormalities to deletion 5q were: del(12p), trisomy 21, trisomy 8 and 
del(20q), the incidences of which were within the ranges reported in the 
literature.23 It should be noted, however, that the number of aberrations of 
chromosome 7 (-7/7q-) occurring as the sole additional abnormality in this 
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series (n=5) was not large enough to help us to clarify its prognostic value, 
though a slightly non-statistically significant decrease in OS was observed in 
this subset of patients (data not shown).  
Regarding breakpoints observed in our series, our results agree with previous 
studies.9,24-26 However, some of the variability in the reported deletion 
breakpoints may result from the difficulties of interpretation in suboptimal 
chromosomal preparations and the inter-personal variability as well. For the 
whole series, we observed an association between the deleted regions and its 
outcomes, in terms of OS. Nevertheless, we did not find association of the 
length of the deleted segment with respect to OS. Of note, no significant 
differences in breakpoints were observed between patients with the ‘5q- 
syndrome’ and the rest of the series, in contrast with which was previously 
reported.27  
Karyotype complexity is a well-known prognostic factor in MDS.5,8,10,11,28,29 
However, in MDS patients with deletion 5q prognostic value of the number of 
chromosomal abnormalities in addition to deletion 5q (for example, complexity 
of the karyotype) is still a matter of debate, with previous reports showing 
conflicting results. In 2003, Stewart et al.30 analyzed outcomes of 
haematopoietic stem cell transplants in patients with MDS or AML and deletion 
5q as the sole karyotypic abnormality (n=20) vs. deletion 5q in combination with 
other chromosomal abnormalities (n=37). Overall, patients with deletion 5q as 
the sole karyotypic abnormality had lower rate of relapse and increased 
relapse-free survival. In addition to that, the blast count (<5%) was the only 
factor significantly associated with relapse-free survival. In 2004, Giagounidis et 
al.9, reported a series of 76 MDS patients with deletion 5q in which those with 
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one additional abnormality to deletion 5q had a significant worse prognosis. 
However, the analysis was restricted to a subset of just 10 patients with a single 
additional abnormality. Recently, Holtan et al.31, studying 130 deletion 5q MDS 
patients (including 39 with isolated deletion 5q and 16 plus one additional 
aberration) found similar survival for these two groups. Finally, in the largest 
series reported before the present one, Haase et al.5 did not find statistical 
differences in OS between both groups of patients (82 patients with one 
additional abnormality out of 168 deletion 5q MDS patients). In the present 
enlarged series, we also failed to find a significantly different OS between 
patients with a sole deletion 5q (n=275) and those with a single additional 
abnormality (n=89), despite this latter group showed a somewhat shorter 
survival (46.0 vs. 63.4 months; P=0.131). Nevertheless, this similarity was not 
kept for the risk of AML evolution, an outcome not extensively evaluated in 
previous studies, as patients with a single additional abnormality showed a 
higher risk of evolution to AML (57.6% vs. 21.1% at 5 years, P<0.001). Patients 
with two or more additional abnormalities had a dismal prognosis in terms of OS 
and risk to AML transformation. The data regarding transformation to AML will 
be of importance, specially, in the assessment of clinical trials, a controversial 
point for the approval of drugs in haematological malignancies. 
Multivariate analysis confirmed the independently adverse impact of the 
complexity of the karyotype (for instance, plus ≥2 additional aberrations) in both 
OS and risk of AML transformation. By contrast, differences in outcome 
between patients with isolated deletion 5q and those with a single additional 
abnormality seem not to be fully attributable to the extra aberration per se. In 
fact, these two groups showed significant differences in variables such as BM 
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blasts and platelet count (Table 2), which could account, at least in part, for the 
different outcomes. 
Nowadays, the IPSS score10 still being the gold standard for MDS stratifications 
and prognostication. In 2007 Malcovati et al. published a new scoring system 
based on the WHO classification, called WHO classification-based prognostic 
scoring system (WPSS), that includes the IPSS cytogenetic risk categories, the 
WHO classification, and transfusion requirements32. Unfortunately, this latter 
variable was not available in most of our patients and, thus, we were not able to 
evaluate the potential prognostic importance of transfusion requirements and 
WPSS in MDS patients with 5q deletion. 
Finally, we analyzed the characteristics and outcome of 148 patients fulfilling 
the ‘5q- syndrome’ WHO 2001 definition (144 with available follow-up data). 
WHO 2008 classification3 restricts this diagnosis to MDS patients with isolated 
deletion 5q without any additional chromosomal abnormality (with the exception 
of a loss of the Y chromosome) and a BM blast count below 5%. Ironically, none 
of the patients with deletion 5q MDS in the present series showed a concurrent 
loss of Y chromosome, although it was observed in the context of complex 
karyotypes. The multivariate analysis of prognostic factors in patients with WHO 
2001-defined ‘5q- syndrome’ showed that a platelet count lower or equal to 
150×109/L and advanced age were adversely related to OS. By contrast, none 
of the parameters evaluated demonstrated a significant association with AML 
transformation risk. This is the first series that include a large number of cases 
with ‘5q- syndrome’ defined according to the WHO classification; our findings 
could help to a better prognostic characterization of this entity. Although, 
Patnaik et al., in 2010, published a large series fulfilling the current WHO-2008 
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definition, they were as not large as our subset of patients. However, the 
multivariate analysis give additional data, showing that the tranfusion need at 
diagnosis and dysgranulopoiesis are important prognostic factors, as well as 
age.33 Additionally, they contribute with data from molecular studies, very useful 
in this subset of patients. They performed mutational analysis from JAK2, MPL 
and IDH1 genes, which revealed mutations except for the IDH1 gene, they are 
more associated with high-risk MDS or AML.33,34 
In summary, the results of this retrospective collaborative study, which is the 
largest available series of patients with primary MDS and deletion 5q, most of 
them receiving supportive care, demonstrate the independent prognostic impact 
of the number of additional chromosomal abnormalities to deletion 5q, to 
question the currently accepted WHO definition of the ‘5q- syndrome’. In 
addition, it is the first to show the prognostic importance of platelet count and 
age in patients with ‘5q- syndrome’. Further, this series could be very useful for 
the design of clinical trials in MDS patients with deletion 5q. This may be of 
special relevance in view of the controversies arisen by the results observed in 
patients treated with lenalidomide. 
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FIGURE LEGENDS 
 
Figure 1.  
Incidence of the three defined cytogenetic categories (isolated del(5q), 
del(5q) + 1, del(5q) + ≥2) among the different morphological subtypes. A. 
According to the FAB classification. B. According to the WHO classification. 
Abbreviations: RA, refractory anaemia; RARS, RA with ringed sideroblasts; 
RAEB, RA with excess of blasts; RCMD, refractory cytopenia with multilineage 
dysplasia; RCMD-RS, RCMD with ringed sideroblasts; MDS-U, MDS 
unclassifiable. 
 
Figure 2. 
Kaplan-Meier curves according to the three defined cytogenetic 
categories (isolated del(5q), del(5q) + 1, del(5q) + ≥2). A. Actuarial probability 
of overall survival. B. Cumulative probability of AML transformation. 
 
Figure 3.  
Kaplan-Meier curves according to the three defined cytogenetic 
categories (isolated del(5q), del(5q) + 1, del(5q) + ≥2) in patients with <5% 
and <10% blasts in bone marrow (BM). A. Actuarial probability of overall 
survival for patients with a BM blast count <5%. B. Cumulative probability of 
AML transformation for patients with a BM blast count <5%. C. Actuarial 
probability of overall survival for patients with a BM blast count <10%. D. 
Cumulative probability of AML transformation for patients with a BM blast count 
<10%. 
 1
Table 1. Patient characteristics 
 
Characteristic Number of patients, n (%) 
Total number of patients 541 
Age 532 
 < 60 years 129 (24.2) 
 ≥ 60 years 403 (75.8) 
Sex 541 
 Male 183 (33.8) 
 Female 358 (66.2) 
Haemoglobin 438 
 < 10 g/dL 308 (70.3) 
 ≥ 10 g/dL 130 (29.7) 
Absolute neutrophil count 320 
 < 1.8 x 109/L 156 (48.8) 
 ≥ 1.8 x 109/L 164 (51.2) 
Platelet count 439 
 < 100 x 109/L 129 (29.4) 
 ≥ 100 x 109/L 310 (70.6) 
Cytopenias  325 
 None 48 (14.8) 
 One 115 (35.4) 
 Two 105 (32.3) 
 Three 57 (17.5) 
BM blast count 497 
 <5 % 293 (58.8) 
 5-10 % 90 (18.1) 
 11-20 % 115 (23.1) 
FAB sybtype  508 
 RA 250 (49.2) 
 RARS 41 (8.1) 
 RAEB 217 (42.7) 
WHO subtype 373 
 RA 4 (1.1) 
 RARS 2 (0.5) 
 RCMD 18 (4.8) 
 2
 RCMD-RS 11 (2.9) 
 ‘5q- syndrome’ 148 (39.7) 
 RAEB-1 81 (21.7) 
 RAEB-2 108 (29.0) 
 MDS-U 1 (0.3) 
Karyotype complexity 541 
 Isolated 5q- 299 (55.3) 
 5q- + 1 abnormality 93 (17.2) 
 5q- + 2 abnormalities 26 (4.8) 
 5q- + 3 abnormalities 21 (3.9) 
 5q- + 4 abnormalities 19 (3.5) 
 5q- + ≥5 abnormalities 83 (15.3) 
Deletion 5q breakpoints 383 
 q13q31 61 (15.9) 
 q13q33 189 (49.4) 
 q22q33 30 (7.8) 
 q12q33 13 (3.4) 
 q14q34 10 (2.6) 
 Others 80 (20.9) 
Percentage of del(5q) metaphases 365 
 <100 % 233 (63.8) 
 100 % 132 (36.8) 
IPSS risk group 329 
 Low 89 (27.1) 
 Intermediate-1 110 (33.4) 
 Intermediate-2 83 (25.2) 
 High 47 (14.3) 
 
Abbreviations: BM, bone marrow; RA, refractory anaemia; RARS, RA with ringed sideroblasts; RAEB, RA with excess of blasts; RCMD, 
refractory cytopenia with multilineage dysplasia; RCMD-RS, RCMD with ringed sideroblasts; MDS-U, MDS unclassifiable. 
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Table 2. Patient characteristics according to the karyotype complexity 
 
 
 
Isolated del(5q) [1] 
 del(5q) + 1 abnormality 
[2] 
 del(5q) + ≥2 
abnormalities [3] 
 
P value 
 
 Median      
(Q1-Q3) 
n (%) 
 Median      
(Q1-Q3) 
n (%) 
 Median     
(Q1-Q3) 
n (%) 
 
[1] vs. [2] [1] vs. [3] [2] vs. [3]
Age   68 (59-76) 292  67 (59-76) 93  68 (59-76) 147  0.772a 0.357a 0.294a 
<60 years   77 (26.4)   24 (25.8)   28 (19.0)     
≥60 years   215 (73.6)   69 (74.2)   119 (81.0)     
Sex   299   93   149  0.440b <0.001b 0.031b 
Male   84 (28.1)   30 (32.3)   69 (46.3)     
Female   215 (71.9)   63 (67.7)   80 (53.7)     
Haemoglobin   8.9 (2.0)* 255  9.3 (1.9)* 77  8.7 (1.6)* 106  0.327c 0.455c 0.078c 
<10 g/dL   176 (69)   47 (61.0)   85 (80.2)     
≥10 g/dL   79 (31)   30 (39.0)   21 (19.8)     
Absolute 
neutrophil count 
 
2.2 (1.4-3.0) 167 
 
1.6 (1.1-2.8) 49 
 
1.1 (0.5-2.2) 104 
 
0.111a <0.001a 0.003a 
<1.8 x 109/L   58 (34.7)   25 (51.0)   73 (70.2)     
≥1.8 x 109/L   109 (65.3)   24 (49.0)   31 (29.8)     
Platelet count 
 243        
(145-377) 
253 
 196       
(106-295) 
79 
 59         
(33-113) 
107 
 
0.006a <0.001a <0.001a 
<100 x 109/L   35 (13.8)   18 (22.8)   76 (71.0)     
≥100 x 109/L   218 (86.2)   61 (77.2)   31 (29.0)     
 BM blasts 
 3.0          
(1.0-5.0) 
275 
 4.0         
(2.0-10.0) 
81 
 9.0         
(4.0-13.0) 
142 
 
0.009a <0.001a <0.001a 
<5 %   203 (73.8)   51 (63.0)   39 (27.5)     
5-10 %   43 (15.6)   9 (11.1)   38 (26.7)     
11-20 %    29 (10.5)   21 (25.9)   65 (45.8)     
Percentage of 
del(5q) 
metaphases 
 
75           
(52.2-100.0) 
179 
 
88.7         
(64.4-100.0) 
76 
 
98.1        
(69.8-100.0)
110 
 
0.227b <0.001b 0.051b 
<100 %   129 (72.1)   49 (64.5)   55 (50.0)     
100 %   50 (27.9)   27 (35.5)   55 (50.0)     
Cytopenias   170   50   105  0.074d <0.001b <0.001d 
None   38 (22.4)   7 (14.0)   3 (2.8)     
One    79 (46.5)   21 (42.0)   15 (14.3)     
Two    46 (27.0)   15 (30.0)   44 (41.9)     
Three   7 (4.1)   3 (14.0)   43 (41.0)     
 4
IPSS risk group   173   51   105  <0.001d <0.001b <0.001b 
Low   89 (51.4)   0 (0.0)   0 (0.0)     
Intermediate-1    65 (37.6)   34 (66.7)   11 (10.5)     
Intermediate-2   18 (10.4)   15 (29.4)   50 (47.6)     
High    1 (0.6)   2 (3.9)   44 (41.9)     
FAB subtype   277   85   146  0.023b <0.001b <0.001b 
RA   182 (65.7)   42 (49.4)   26 (17.8)     
RARS   21 (7.6)   11 (12.9)   9 (6.2)     
RAEB    74 (26.7)   32 (37.6)   111 (76.0)     
WHO subtype   217   42   114  <0.001d <0.001d 0.016d 
‘5q- syndrome’   148 (68.2)   0 (0.0)   0 (0.0)     
RA   1 (0.5)   2 (4.8)   1 (0.9)     
RARS   0 (0.0)   1 (2.4)   1 (0.9)     
RCMD   3 (1.4)   8 (19.0)   7 (6.1)     
RCMD-RS   1 (0.5)   5 (11.9)   5 (4.4)     
RAEB-1   35 (16.0)   9 (21.4)   37 (32.4)     
RAEB-2    29 (13.4)   17 (40.5)   62 (54.4)     
MDS-U   0 (0.0)   0 (0.0)   1 (0.9)     
 
Q1, percentile 25; Q3, percentile 75; a Mann-Whitney U test; b Chi-square test; c One-Way ANOVA with Post-Hoc Tukey’s test; d Fisher’s 
exact test. 
* This value corresponds to the mean and standard deviation, in brackets. 
 
Abbreviations: BM, bone marrow; RA, refractory anaemia; RARS, RA with ringed sideroblasts; RAEB, RA with excess of blasts; RCMD, 
refractory cytopenia with multilineage dysplasia; RCMD-RS, RCMD with ringed sideroblasts; MDS-U, MDS unclassifiable. 
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Table 3. Comparative of clinical characteristics of patients with ‘5q- syndrome’ 
 
 ‘5q- syndrome’   ‘non 5q- syndrome’   
 Median (Q1-Q3) n (%)  Median (Q1-Q3) n (%)  P value 
Age  70 (59-79) 147  67 (60-75) 385  0.070a 
<60 years  39 (26.5)   90 (23.4)   
≥60 years  108 (73.5)   295 (76.6)   
Sex  148   393  0.035b 
Male  43 (29.1)   140 (35.6)   
Female  105 (70.9)   253 (64.4)   
Haemoglobin  9.0 (1.9)* 133  8.9 (1.9)* 305  0.420c 
<10 g/dL  92 (69.2)   216 (70.8)   
≥10 g/dL  41 (30.8)   89 (29.2)   
Absolute neutrophil count 2.2 (1.5-3.3) 86  1.6 (0.9-2.7) 234  <0.001 a 
<1.8x109/L  26 (30.2)   130 (55.6)   
≥1.8x109/L  60 (69.8)   104 (44.4)   
Platelet count  295 (174-412) 130  138 (60-262) 309  <0.001a 
<100x109/L  13 (10.0)   116 (37.5)   
≥100x109/L  117 (90.0)   193 (62.5)   
 BM blasts count  2.0 (1.0-3.0) 141  6.0 (3.0-11.0) 357  <0.001a 
<5 %  141 (100.0)   152 (42.6)   
5-10 %  0 (0.0)   90 (25.2)   
11-20 %  0 (0.0)   115 (32.2)   
IPSS score  89   240  <0.001b 
Low  70 (78.7)   19 (7.9)   
Intermediate-1  19 (21.3)   91 (37.9)   
Intermediate-2  0 (0.0)   83 (34.6)   
High  0 (0.0)   47 (19.6)   
Percentage of del(5q) 
metaphases 
70.0 (40.0-93.1) 73 
 
90.0 (61.1-100.0) 292 
 
<0.001b 
<100 %  60 (82.2)   173 (59.2)   
100 %  13 (17.8)   119 (40.8)   
 
Q1, percentile 25; Q3, percentile 75; a MannWhitney U test; b Chi-square test; c Student-t test. 
* This value corresponds to the mean and standard deviation, in brackets. 
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Table 4. Results of univariate analyses of prognostic factors for OS and AML 
transformation in the overall series 
 
 Overall survival  AML transformation 
 n (%) 
Median 
survival 
(mo) 
Patients 
alive at 5 
years  
(%) 
P value n (%) 
Time to 
25% 
probability 
(mo) 
Cumulative 
probability of AML 
evolution at 5 
years (%) 
P value 
Age 506 (93.5) <0.001 297 (54.9) 0.042 
 < 60 years 121 (23.9) 80.0 52.4 
 
66 (22.2) 13.5 47.7  
 ≥ 60 years 385 (76.1) 33.0 28.1 231 (77.8) 41.8 36.0  
Sex 512 (94.6) <0.001 299 (55.3) 0.029 
 Male 174 (34.0) 25.0 21.2 
 
108 (36.1) 14.9 52.1 
  Female 338 (66.0) 44.9 41.9 191 (63.9) 42.1 32.4 
Haemoglobin 429 (79.3) 0.030 290 (53.6) 0.252 
 <10 g/dL 302 (70.4) 35.0 33.7 
 
200 (69.0) 22.9 41.9 
  ≥10 g/dL 127 (29.6) 54.5 42.7 90 (31.6) 44.2 32.8 
Absolute 
neutrophil count 318 (58.8) <0.001 285 (52.7) 0.004 
 <1.8 x 109/L 155 (48.7) 15.0 17.1 
 
136 (47.7) 13.2 47.3 
  ≥1.8 x 10
9/L 163 (51.3) 38.7 45.0 149 (52.3) 51.6 28.7 
Platelet count 428 (79.1) <0.001 290 (53.6) <0.001 
 <100 x 109/L 127 (29.7) 8.2 8.3 
 
100 (34.5) 6.7 67.6 
  ≥100 x 10
9/L 301 (70.3) 47.0 57.1 190 (65.5) 48.6 30.4 
Cytopenias 323 (59.7) <0.001 286 (52.9) <0.001 
 None 47 (14.6) 65.9 53.4 
 
44 (15.4) NR 15.9 
 
 One 115 (35.6) 50.9 36.1 100 (35.0) 34.5 44.8 
 Two 104 (32.2) 19.7 20.5 92 (32.1) 15.0 32.2 
 Three 57 (17.6) 7.9 5.2 50 (17.5) 67 76.6 
BM blast count 479 (88.5) <0.001 296 (54.7) <0.001 
 <5 % 277 (57.8) 50.9 44.3 
 
151 (51.0) 51.1 31.3 
 
 5-10 % 88 (18.4) 19.7 26.2 63 (21.3) 13.5 42.1 
 11-20 % 114 (23.8) 11.0 12.5 82 (27.7) 8.4 55.9  
IPSS risk group 327 (60.4) <0.001 289 (53.4) <0.001 
 Low 88 (26.9) 58.9 49.1 
 
78 (27.0) 65.0 21.2 
 
 Intermediate-1 109 (33.3) 45.0 34.3 94 (32.5) 52.4 25.6 
 Intermediate-2 83 (25.4) 13.4 15.2 74 (25.6) 9.1 65.0 
 High 47 (14.4) 6.5 0.0 43 (14.9) 5.2 100.0 
FAB subtype 488 (90.2) <0.001 2889 (53.4) <0.001 
 RA 232 (47.5) 57.0 47.3 
 
117 (40.5) 51.4 29.8 
 
 RARS 41 (8.4) 38.9 36.1 20 (6.9) 10.8 - 
 RAEB 215 (44.1) 14.9 17.3 152 (52.6) 9.7 48.1 
WHO subtype 362 (66.9) <0.001 255 (47.1) <0.001 
 ‘5q- syndrome’ 140 (38.7) 65.9 51.3 
 
86 (33.7) 65.0 18.2 
  RA 4 (1.1) 31.6 33.3 3 (1.2) - 100.0 
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 RARS 2 (0.6) 2.7 0.0 2 (0.8) - 100.0 
 RCMD 17 (4.7) 31.0 15.9 10 (3.9) - 100.0 
 RCMD-RS 11 (3.0) 20.8 16.4 6 (2.4) 4.7 100.0 
 RAEB-1 79 (21.8) 18.0 20.0 62 (24.3) 15.4 30.6 
 RAEB-2 108 (29.8) 10.4 13.0 85 (33.3) 8.7 63.4 
 MDS-U 1 (0.3) 9.7 0.0 1 (0.4) - - 
Percentage of 
del(5q) 
metaphases 
353 (65.2) <0.001 250 (46.2) 0.003 
 <100 % 225 (63.7) 39.6 35.2 
 
170 (68.0) 51.1 34.4 
  100 % 128 (36.3) 16.2 20.1 80 (42.0) 8.4 53.4 
Deletion 5q 
breakpoints 370 (68.4) 0.008  0.386 
 q13q31 60 (16.2) 57.1 47.4 
 
33 (15.9) 52.4 47.4 
 
 q13q33 181 (48.9) 39.6 38.7 110 (53.2) 26.0 38.7 
 q22q33 30 (8.1) 24.0 28.2 13 (6.3) 13.2 28.2 
 q12q33 13 (3.5) 57.4 46.7 10 (4.8) - 46.7 
 q14q34 10 (2.7) 73.0 33.8 1 (0.5) - 33.8 
 Others 76 (20.6) 19.7 26.9 40 (19.3) 15.4 26.9 
Karyotype 
complexity 512 (94.6) <0.001 299 (55.3) <0.001 
 Del(5q) 275 (53.7) 63.4 50.6 
 
160 (53.5) 65.0 21.1 
 
Del(5q) + 1 89 (17.4) 46.0 40.4 43 (14.4) 14.9 57.6 
Del(5q) + 2 26 (5.1) 13.9 0.0 16 (5.4) 4.7 100.0 
Del(5q) + 3 21 (4.1) 8.1 0.0 15 (5.0) 2.6 100.0 
Del(5q) + 4 19 (3.7) 7.6 0.0 13 (4.3) 3.9 100.0 
Del(5q) + ≥5 82 (16.0) 5.7 2.3 52 (17.4) 4.2 100.0 
 
Abbreviations: BM, bone marrow; NR: not reached; RA, refractory anaemia; RARS, RA with ringed sideroblasts; RAEB, RA with excess 
of blasts; RCMD, refractory cytopenia with multilineage dysplasia; RCMD-RS, RCMD with ringed sideroblasts; MDS-U, MDS 
unclassifiable. 
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Table 5. Results of multivariate analysis of prognostic factors for OS and AML transformation in the overall series 
 
 
 Overall survival AML transformation 
Variable Categories Hazard ratio (95% CI) P value Categories 
Hazard ratio    
(95% CI) P value 
Karyotype complexity del(5q) and del(5q)+1 vs. del(5q)+≥2 4.1 (2.9-5.7) <0.001 
del(5q) vs. 
del(5q)+1 vs. 
del(5q)+≥2 
2.9 (2.0-4.1) <0.001 
Platelet count ≤150 x 10
9/L vs.   
>150 x 109/L 2.0 (1.5-2.8) <0.001 
≤150 x 109/L vs. 
>150 x 109/L 2.2 (1.2-3.9) 0.001 
BM blasts <5% vs. 5-10% vs. 11-20% vs. >20% 1.4 (1.2-1.7) <0.001 <5% vs. >5% 1.4 (1.1-1.9) 0.016 
Age <60 years vs.         ≥60 years 1.6 (1.2-2.3) 0.001 - - - 
Sex Female vs. Male 0.7 (0.5-0.9) 0.020 - - - 
 
Abbreviations: CI, confidence interval; BM, bone marrow. 
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